Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer

Monday, February 19, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the association between PBRM1 loss and increased sensitivity to MCL1 and CDK9 inhibition in clear cell renal cancer. This discovery suggests that patients with PBRM1 loss may benefit from targeted therapies that inhibit these proteins. The findings could pave the way for more effective treatment strategies tailored to genetic profiles.
Price reaction · baseline $4.63 (2024-02-16 close) · clean, no other PRLD news in the window
day 0 close
-10.2%
day 1 · peak
-18.4%
day 3
-14.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • PBRM1 loss enhances sensitivity to MCL1 and CDK9 inhibitors.
  • Findings could lead to improved treatment strategies for clear cell renal cancer.
  • Potential for targeted therapies based on genetic markers.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

• About Overview Leadership Board of Directors
• Science Overview Pipeline JAK2V617F KAT6A Precision DACs Discovery Engine Publications
• Investors Overview News & Events News Releases Events & Presentations Financials SEC Filings Quarterly Results Stock Information Stock Quote & Chart Analysts Governance Governance Documents Leadership Committee Composition Investor Resources Investor Faqs Contact IR Email Alerts
• News
• Life at Prelude Overview Open Positions
• Contact
• Overview
• Leadership
• Board of Directors
• Overview
• Pipeline
• JAK2V617F
• KAT6A
• Precision DACs
• Discovery Engine
• Publications
• Overview
• News & Events News Releases Events & Presentations
• Financials SEC Filings Quarterly Results
• Stock Information Stock Quote & Chart Analysts
• Governance Governance Documents Leadership Committee Composition
• Investor Resources Investor Faqs Contact IR Email Alerts
• News Releases
• Events & Presentations
• SEC Filings
• Quarterly Results
• Stock Quote & Chart
• Analysts
• Governance Documents
• Leadership
• Committee Composition
• Investor Faqs
• Contact IR
• Email Alerts
• Overview
• Open Positions
Norman Fultang, Ashley M. Schwab, Sophia McAneny-Droz, Alexander Grego, Stephanie Rodgers, Brian Vidal Torres, Diane Heiser, Peggy Scherle, Neha Bhagwat

Frequently Asked Questions

What is the significance of PBRM1 loss?

PBRM1 loss is associated with increased sensitivity to MCL1 and CDK9 inhibitors in clear cell renal cancer.

How does PBRM1 loss affect treatment options?

Patients with PBRM1 loss may benefit from targeted therapies that inhibit MCL1 and CDK9.

What types of cancer are discussed in the article?

The article focuses on clear cell renal cancer and its genetic implications.

What are MCL1 and CDK9?

MCL1 and CDK9 are proteins that, when inhibited, can enhance treatment efficacy in certain cancers.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PBRM1 MCL1 CDK9 clear cell renal cancer inhibition
Last updated: Feb 19, 2024

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →